Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 A Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients.

Slides:



Advertisements
Similar presentations
The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.
Advertisements

Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
TOTAL Culprit lesion thrombus burden after manual aspiration thrombectomy or PCI alone in STEMI The OCT Substudy of the TOTAL (ThrOmbecTomy versus PCI.
on behalf of the TOTAL Investigators
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.
Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,
Academic Medical Center Amsterdam Interventional Cardiology JACC Intv Oct; 2 (10): Within the past 12 months, our institution has had a financial.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
The Impact of Thrombus Aspiration on 1-year Mortality in Primary PCI for ST-Elevation Myocardial Infarction, ACSIS 2010 Experience Mady Moriel, Shlomi.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
STATINS PRE-PCI: A Prospective, Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina Josef VESELKA CardioVascular Center.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
Disclosure Statement of Financial Interest
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved. UC ML.
New strategies and perfusion/aspiration devices for primary PCI Sandra Garcia Cruset, PhD. Cordynamic B.U. Marketing Manager.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
: PROFI : A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Filter Embolic Protection in Patients Undergoing Carotid Stenting Klaudija.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic.
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Updates From NOTION: The First All-Comer TAVR Trial
Presenter Disclosure Information
OCT-Guided PCI What needs to be done to establish criteria?
Prospective evaluation of where reperfusion ventricular arrhythmia “bursts” fit into optimal reperfusion in STEMI  Kirian van der Weg, Wichert J. Kuijt,
European Society of Cardiology 2003
Prospective evaluation of where reperfusion ventricular arrhythmia “bursts” fit into optimal reperfusion in STEMI  Kirian van der Weg, Wichert J. Kuijt,
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Published in the European Heart Journal
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Infarct Size after Primary Angioplasty Patients With Bivalirudin
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 A Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients with Acute Myocardial Infarction Undergoing Primary PCI The PREPARE Trial PRoximal Embolic Protection in Acute MI and Resolution of ST-Elevation Karel T. Koch Joost D.E. Haeck, Jan G.P. Tijssen, Luc Bilodeau*, René J. van der Schaaf, José P.S. Henriques, Allard van der Wal, Jan Baan Jr., Marije M. Vis, Jan J. Piek, Mitchell W. Krucoff †, Robbert J. de Winter. Academic Medical Center - University of Amsterdam, The Netherlands *Institut de Cardiologie de Montréal, QC, Canada † Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial RelationshipCompany Grant/Research Support: Educational Grant St. Jude Medical Disclosure statement of financial interest

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Inadequate myocardial reperfusion relates to prognosis, even in the presence of adequate epicardial flow. Embolization of atherothrombotic material plays a crucial role in microvascular obstruction and impaired myocardial perfusion. The Proxis™ device is a combined system of proximal embolic protection and thrombus aspiration. The device has been shown feasible and safe in primary PCI *. The PREPARE Trial was designed to evaluate primary PCI with the Proxis system compared to primary PCI alone. *Koch KT et al. Rev Cardiovasc Med. 2007;8(3): Background

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Full length flexible catheter 6F and 7F GC compatible Sealing balloon at the tip CO 2 based inflation device Deployed proximal to target lesion before crossing Inflation of balloon suspends antegrade flow during lesion intervention Stagnated blood and emboli liberated during intervention are retrieved by gentle aspiration Proxis embolic protection system Proxis™ embolic protection system (St. Jude Medical, St. Paul, MN, USA)

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 PRoximal Embolic Protection in Acute MI and Resolution of ST-ElevationPRoximal Embolic Protection in Acute MI and Resolution of ST-Elevation Investigator-initiated randomized trialInvestigator-initiated randomized trial Comparison of primary PCI with Proxis system versus primary PCI aloneComparison of primary PCI with Proxis system versus primary PCI alone Open trial with blinded evaluation of end pointsOpen trial with blinded evaluation of end points Participation of 2 centersParticipation of 2 centers 140 patients in each study arm140 patients in each study arm PREPARE Trial

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Inclusion criteria Consecutive STEMI patients ≤ 6 hConsecutive STEMI patients ≤ 6 h ST-segment elevation ≥ 2 mm in ≥ 2 leadsST-segment elevation ≥ 2 mm in ≥ 2 leads TIMI flow grade 0 to 1 at first angiogramTIMI flow grade 0 to 1 at first angiogram Coronary anatomy suitable for ProxisCoronary anatomy suitable for Proxis ECG suitable for ST-segment resolution evaluationECG suitable for ST-segment resolution evaluation Exclusion criteria Recurrence of MI in same areaRecurrence of MI in same area Prior CABG or lyticsPrior CABG or lytics Patient selection

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 UFH 70 U/kg ASA 300 mg Clopidogrel 600 mg Continuous ST Holter Coronary angiogram STEMI ≤ 6 h Primary PCI alone Clinical follow up at 30 days Primary PCI with Proxis PREPARE Trial Study flow chart R 24 h

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Primary end point ST-segment elevation resolution (STR) over time* ST-segment elevation resolution (STR) over time* Secondary end points TIMI graded flow TIMI graded flow Myocardial blush grade Myocardial blush grade Angiographic signs of distal embolization Angiographic signs of distal embolization Composite of death, MI, TVR, and stroke at 30 days Composite of death, MI, TVR, and stroke at 30 days End points *Duke Clinical Research Institute Core Lab

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Patient characteristics Age62 ± ± 11 Male 80%80% Family history CAD35%38% Hypercholesterolemia21%13% Current smoking 50%65% Hypertension31%23% Diabetes12%6% Previous MI6%9% Multivessel disease33%31% Symptoms to balloon (min) Proxis n = 141 Control n = 143

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Infarct related artery RCA61%60% LAD29%29% LCx10%11% Pre-PCI TIMI graded flow 090%89% 19%8% 21% 4% Lesion characteristics Proxis n = 141 Control n = 143

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Procedural characteristics *P<0.05; IQR interquartile range Procedural success100%99% Proxis placed94%─ Predilatation and stenting87%76% Direct stenting 11%19% Balloon angioplasty 3% 6% GP IIb/IIIa receptor antagonists 43%35% Additional thrombus aspiration 6%6% Pathology confirmed thrombus 75% ─ Puncture to balloon (min) Median 17 14* IQR * Proxis n = 141 Control n = 143

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Complete (>70%) STR (Fisher’s Exact Test) Proxis n = 141 Control n = 143 P-value *Primary endpoint

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Immediate66% (85/129) 50% (67/135) Complete (>70%) STR (Fisher’s Exact Test) Proxis n = 141 Control n = 143 P-value *Primary endpoint

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Immediate66% (85/129) 50% (67/135) min75% (91/122) 66% (86/130) min80% (101/126) 72% (93/129) min81% (100/124) 74% (97/131) min78% (98/126) 76% (100/131) 0.88 Complete (>70%) STR (Fisher’s Exact Test) Proxis n = 141 Control n = 143 P-value

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Complete STR over time Lastcontrast Time after last contrast, min Patients with complete STR, % Control Proxis P=0.009

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Immediate73 ± 2763 ± min79 ± 2175 ± min82 ± 2078 ± min82 ± 1980 ± min82 ± 1981 ± Mean % STR P-value * Proxis n = 141 Control n = 143 Mean (SD); * T-Test

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Angiographic parameters Proxis n = 141 Control n = 143 *Cochran-Armitage Test † Fisher’s Exact Test Post-PCI TIMI graded flow 393%87% 27%11%0.06 * 0-10%2% 0-10%2% Myocardial blush grade 381%83% 216%11%0.93 * 0-14%6% 0-14%6% Distal embolization (yes/no) 10%14%0.36 † P-value

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Death22 MI23 TVR36 Stroke01 MACCE * 6 (4%) 10 (7%) no complications at Proxis landing zone no complications at Proxis landing zone Clinical events at 30 days Proxis n = 141 Control n = 143 For descriptive purposes only; no statistical comparisons done *ARC MACCE definition Circ. 2007; 115: 2344–2351

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 The Proxis system is feasible and safe in the setting of STEMI, and effectively retrieves embolic debris in most patients. In conclusion

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 The Proxis system is feasible and safe in the setting of STEMI, and effectively retrieves embolic debris in most patients. Complete STR was better in Proxis treated patients compared to control patients. The difference in STR immediately after PCI was highly statistically significant (p=0.009). In conclusion

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 The Proxis system is feasible and safe in the setting of STEMI, and effectively retrieves embolic debris in most patients. Complete STR was better in Proxis treated patients compared to control patients. The difference in STR immediately after PCI was highly statistically significant (p=0.009). The results of the PREPARE trial suggest that primary PCI with combined proximal embolic protection and aspiration leads to better immediate microvascular flow in STEMI patients. In conclusion

Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 Thank you for your attention PREPARE Trial PRoximal Embolic Protection in Acute MI and Resolution of ST-Elevation